Compare RCUS & ANDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | ANDG |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2018 | 2025 |
| Metric | RCUS | ANDG |
|---|---|---|
| Price | $23.08 | $22.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $28.89 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 1.4M | 378.3K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $240,000,000.00 | ★ $810,756,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.57 |
| Revenue Growth | N/A | ★ 26.86 |
| 52 Week Low | $6.50 | $20.00 |
| 52 Week High | $26.40 | $27.51 |
| Indicator | RCUS | ANDG |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | N/A |
| Support Level | $20.70 | N/A |
| Resistance Level | $23.40 | N/A |
| Average True Range (ATR) | 1.44 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 61.75 | 0.00 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Andersen Group Inc is a provider of independent tax, valuation and financial advisory services to individuals and family offices, businesses and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services.